HSBC Continental Europe1 Interim Results 2022
14.9.2022 17:46:00 EEST | Business Wire | Press release
On 29 July 2022, HSBC Continental Europe’s Board of Directors approved the bank’s consolidated financial statements for the first half of 2022.
HSBC Continental Europe’s performance during the first half of 2022 was positive with continued profitability driven by growth in wholesale banking revenues, demonstrating the strength of our global franchise and international connectivity, coupled with low credit losses and a favourable cost performance. With inflationary pressure across Europe and the ongoing Russia-Ukraine war, we expect to be operating in a more difficult environment for the remainder of the year.
Reported consolidated profit before tax was €184m, down from €187m in the first half of 2021, and included an exceptional loss and related impairments of €111m recognised in relation to the planned sale of HSBC Continental Europe’s operations in Greece.
Reported net operating income before change in expected credit losses and other credit impairment charges was €1,218m, down from €1,296m in the first half of 2021, including the exceptional loss recognised in relation to the planned sale of the operations in Greece and a less favourable PVIF movement – €123m in the first half of 2022, compared with a favourable movement of €171m in the first half of 2021. These impacts were largely offset by growth in Commercial Banking and Global Banking, which benefitted from increased client activity and rising interest rates. In addition, Markets and Securities Services revenues increased due to higher transaction volumes, notably in Global Foreign Exchange and Securities Services.
Reported change in expected credit losses and other credit impairment charges was nil, compared to a release of €1m in the first half of 2021. The deterioration of forward-looking economic conditions driven by the rising risk of stagflation and disruption to energy supply was offset by the release of Stage 3 provisions.
Reported operating expenses were €1,034m, down from €1,111m in the first half of 2021. The decrease was due to the recognition of a recovery of VAT paid in 2021 and lower staff costs, partly offset by transformation related costs.
Reported profit attributable to shareholders of the parent company was €127m for the half year to 30 June 2022, compared with €153m in the first half of 2021.
The consolidated balance sheet of HSBC Continental Europe showed total assets of €239bn at 30 June 2022, compared to €223bn at 31 December 2021 with the increase mainly driven by mark-to-market movements on derivatives.
At 30 June 2022, HSBC Continental Europe reported a liquidity coverage ratio (LCR)2 of 145% and a net stable funding ratio (NSFR)3 of 129%. The bank’s fully loaded common equity tier 1 (CET1) ratio was 13.7% and the fully loaded total capital ratio was 18.7% The fully loaded leverage ratio was 3.9%. The solvency ratio of the Life Insurance subsidiary was 263%4.
Planned sale of Greece branch operations and retail banking business in France
Our business transformation has continued to progress at pace, with the signing of a sale and purchase agreement for the sale of our branch operations in Greece to Pancreta Bank SA on 24 May 2022. This followed the completion of the works council consultations. Completion of the potential transaction is subject to regulatory approval and is currently expected to finalise towards the end of the first half of 2023.
As at 30 June 2022, €2.1bn in total assets, including €0.4bn of customer loan balances and €2.3bn in total liabilities, including €2.2bn of customer accounts were reclassified as held for sale in accordance with IFRS 5 and losses and impairments of €111m were recognised for the planned sale of Greece branch operations.
As previously disclosed, we remain on track to complete the sale of our retail banking business in France in the second half of 2023.
Appendix
Interim accounts were subject to a limited review by the statutory auditors.
Summary consolidated income statement
|
€m |
Half year to
|
Half year to
|
Half year to
|
|
Net interest income |
556 |
480 |
507 |
|
Net fee income |
485 |
457 |
458 |
|
Net income/(expense) from financial instruments held for trading or managed on a fair value basis |
211 |
90 |
(9) |
|
Other operating income/(expense) |
(34) |
269 |
111 |
|
Net operating income before change in expected credit losses and other credit impairment charges |
1,218 |
1,296 |
1,067 |
|
Change in expected credit losses and other credit impairment charges |
— |
1 |
(34) |
|
Total operating expenses |
(1,034) |
(1,111) |
(935) |
|
Share of profit in associates and joint ventures |
— |
1 |
— |
|
Profit/(loss) before tax |
184 |
187 |
98 |
|
Tax expense |
(57) |
(34) |
17 |
|
Profit/(loss) for the period |
127 |
153 |
115 |
|
Profit/(loss) attributable to shareholders of the parent company |
127 |
153 |
116 |
|
Profit/(loss) attributable to non-controlling interests |
— |
— |
(1) |
PVIF (Present value of in force long-term insurance business)
HSBC Continental Europe, through its HSBC Assurances Vie subsidiary, accounts for its life insurance business using the embedded value method, which provides a comprehensive framework for assessing risk and valuation. PVIF (present value of in force long-term insurance business) is the present value of future profits from existing insurance policies.
The PVIF calculation is based on assumptions that take into account business risks and uncertainties. When projecting cash flows, HSBC Assurances Vie makes a series of assumptions regarding future experience, taking into account local market conditions and management’s judgment of future local trends.
In the first half of 2022, the PVIF movement was favourable by €123m, compared to €171m in the first half of 2021.
Post-balance sheet events
On 20 July 2022, the Board of Directors convened an Extraordinary General Meeting to be held on 2 September 2022 to propose a share capital increase of €1,300m, related to the planned sale of the retail banking business in France.
Alternative performance metrics
To measure our performance, we also use non-GAAP financial measures, including those derived from our reported results that eliminate factors that distort year-on-year comparisons. The ‘adjusted performance’ measure removes the impact of ‘significant items’, listed below, and year-on-year foreign currency translation differences.
|
€m |
Half year to 30 June 2022 |
Half year to 30 June 2021 |
Half year to 31 Dec 2021 |
|
Reported revenue |
1,218 |
1,296 |
1,067 |
|
Significant revenue items |
93 |
26 |
129 |
|
Adjusted revenue |
1,311 |
1,322 |
1,196 |
|
|
|
|
|
|
Reported operating expenses |
(1,034) |
(1,111) |
(935) |
|
Significant cost items |
75 |
30 |
61 |
|
– Impairment of goodwill, intangibles and tangibles |
8 |
(1) |
3 |
|
– Restructuring cost and other significant items |
67 |
31 |
58 |
|
Adjusted operating expenses |
(959) |
(1,081) |
(874) |
Adjusted results by business line
HSBC Continental Europe changed its segmental reporting in the second half of 2021 by splitting the business line ‘Global Banking and Markets’ into three business lines: ‘Markets and Securities Services’, ‘Global Banking’ and ‘Global Banking and Markets Other’. Financials for the first half of 2021 were re-presented accordingly with no impact on the consolidated financial results.
|
|
Wealth and
|
Commercial
|
Markets and
|
Global
|
Global Banking
|
Corporate
|
Total |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
€m |
Half year to 30 June 2022 |
|||||||||||||
|
Net operating income before change in expected credit losses and other credit impairment charges |
467 |
410 |
179 |
251 |
27 |
(23) |
1,311 |
|||||||
|
Change in expected credit losses and other credit impairment charges |
(2) |
11 |
— |
(10) |
1 |
— |
— |
|||||||
|
Total operating expenses |
(361) |
(215) |
(201) |
(140) |
(31) |
(11) |
(959) |
|||||||
|
Share of profit in associates and joint ventures |
— |
— |
— |
— |
— |
— |
— |
|||||||
|
Adjusted profit/(loss) before tax |
104 |
206 |
(22) |
101 |
(3) |
(34) |
352 |
|||||||
|
|
|
|||||||||||||
|
Half year to 30 June 2021 |
||||||||||||||
|
Net operating income before change in expected credit losses and other credit impairment charges |
544 |
363 |
157 |
224 |
30 |
4 |
1,322 |
|||||||
|
Change in expected credit losses and other credit impairment charges |
10 |
(33) |
— |
24 |
— |
— |
1 |
|||||||
|
Total operating expenses |
(397) |
(254) |
(230) |
(137) |
(31) |
(32) |
(1,081) |
|||||||
|
Share of profit in associates and joint ventures |
— |
— |
— |
— |
— |
1 |
1 |
|||||||
|
Adjusted profit/(loss) before tax |
157 |
76 |
(73) |
111 |
(1) |
(27) |
243 |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
|
Half year to 31 December 2021 |
|||||||||||||
|
Net operating income before change in expected credit losses and other credit impairment charges |
394 |
362 |
103 |
279 |
40 |
18 |
1,196 |
|||||||
|
Change in expected credit losses and other credit impairment charges |
10 |
(35) |
— |
(11) |
2 |
— |
(34) |
|||||||
|
Total operating expenses |
(363) |
(181) |
(146) |
(123) |
(33) |
(28) |
(874) |
|||||||
|
Share of profit in associates and joint ventures |
— |
— |
— |
— |
— |
— |
— |
|||||||
|
Adjusted profit/(loss) before tax |
41 |
146 |
(43) |
145 |
9 |
(10) |
288 |
|||||||
HSBC Continental Europe
Headquartered in Paris, HSBC Continental Europe is a subsidiary of HSBC Holdings plc. HSBC Continental Europe includes, in addition to its activities in France, the activities of 10 European branches (Belgium, Czech Republic, Greece, Ireland, Italy, Luxembourg, Netherlands, Poland, Spain and Sweden). HSBC Continental Europe’s mission is to serve customers in continental Europe for their needs worldwide and customers in other Group countries for their needs in continental Europe.
HSBC Holdings plc
HSBC Holdings plc, the parent company of HSBC, is headquartered in London. HSBC serves customers worldwide from offices in 63 countries and territories in its geographical regions: Europe, Asia, North America, Latin America, and Middle East and North Africa. With assets of US$2,985bn at 30 June 2022, HSBC is one of the world’s largest banking and financial services organisations.
Disclaimer
This press release contains certain forward-looking statements with respect to the financial condition, results of operations and business of the entity. Statements that are not historical facts, including statements about the entity’s beliefs and expectations, are forward-looking statements. Words such as ‘expects’, ‘anticipates’, ‘intends’, ‘plans’, ‘believes’, ‘seeks’, ‘estimates’, ‘potential’ and ‘reasonably possible’, variations of these words and similar expressions are intended to identify forward-looking statements. These statements are based on current plans, estimates and projections, and therefore undue reliance should not be placed on them. Forward-looking statements speak only as of the date they are made. HSBC Continental Europe makes no commitment to revise or update any forward-looking statements to reflect events or circumstances occurring or existing after the date of any forward-looking statement. Forward-looking statements involve inherent risks and uncertainties. Readers are cautioned that a number of factors could cause actual results to differ, in some instances materially, from those anticipated or implied in any forward-looking statements.
1 HSBC Continental Europe includes, in addition to its activities in France, the activities of 10 European branches (Belgium, Czech Republic, Greece, Ireland, Italy, Luxembourg, Netherlands, Poland, Spain and Sweden)
2 Computed in respect of the EU Delegated act
3 Computed in respect of CRR II (Regulation EU 2019/876)
4 LCR, NSFR and the solvency ratio of the Life Assurance subsidiary are unaudited
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005368/en/
Contact information
Raphaële-Marie Hirsch
raphaele.marie.hirsch@hsbc.fr
07 64 57 35 55
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
